https://auroraksp.com/index.ph....p/expenses-of-the-co
Fifty researches had been included in the final evaluation. SUV is notably greater in ER-negative (31 scientific studies, SMD 0.66, 0.56-0.77, P 0.0001), PR-negative (30 researches, SMD 0.56; 0.40-0.71, P 0.0001), HER2-positive (32 researches, SMD - 0.29, - 0.49 to - 0.10, P = 0.0043) or Ki-67-p HER2 overexpression has an intermediate effect.Major tumour SUVmax is somewhat greater in ER-negative, PR-negative, HER2-positive and Ki-67-positive breast cancer patients. Luminal t
Like
Comment
Share
